Conversely, while it is improbable that myoma size is reduced to the same extent by relugolix in combination therapy as in monotherapy, add-back therapy remains indispensable to avoid certain AEs associated with the use of the GnRH antagonist in monotherapy. The gene discussed is GNRH1; the disease is benign muscle neoplasm.